Although VEGF is widely recognized as an ideal target for regulating angiogenesis therapies [29, 30], recent evidence has suggested that SDF-1 is a key player in ischemic retinopathies, such as proliferative retinopathy and retinopathy of prematurity [31]. This evidence concerns the gene CXCL12 and retinopathy of prematurity.